Loading...

Miguel Hernandez Pampaloni, MD

TitleAssociate Professor
SchoolUCSF School of Medicine
DepartmentRadiology
Address505 Parnassus Avenue
San Francisco CA 94117
Phone415-514-5681
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Universidad ComplutenseM.D.1991School of Medicine
    Collapse Awards and Honors
    Society of Nuclear Medicine Meeting2002Cardiovascular Young Investigator Award
    Spanish Society of Cardiology Annual Meeting1999Best Communication Award

    Collapse Overview 
    Collapse Overview
    Miguel Hernandez Pampaloni, MD, PhD, is an Associate Professor in Residence and Chief of Nuclear Medicine in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. Dr. Pampaloni is responsible for all clinical administrative coordination, performance and supervision within the section. Dr. Pampaloni earned his PhD in Radiological Sciences from the Universidad Complutense School of Medicine in Madrid, Spain, and he obtained his MD from the Universidad Complutense School of Medicine. Dr. Pampaloni completed a residency in Nuclear Medicine at the San Carlos Hospital in Madrid, Spain, and he completed a residency in Nuclear Medicine at the University of Pennsylvania School of Medicine. Dr. Pampaloni was a postdoctoral fellow in Cardiovascular Nuclear Medicine at the David Geffen School of Medicine at UCLA, and he was a clinical research fellow in PET Cardiology at the Imperial College in London, England. Dr. Pampaloni joined the UCSF Nuclear Medicine Section as an Assistant Professor in 2009.

    Dr. Pampaloni has two main research interests: applications of molecular imaging into the cardiovascular field and oncology. He is interested in assessing the pathophysiological changes in the inflammatory process at the base of the coronary artery disease by non-invasive evaluation of endothelial function with positron emission tomography. He is particularly interested in developing a molecular imaging model to assess quantitatively the initial changes in the atherosclerotic process, which may help for an early, preclinical, diagnosis. As part of vascular biology characteristics, he is interested in applying new developed radioligands to target specific processes in the angiogenesis of cancer.

    Dr. Pampaloni has written over 40 articles, 6 book chapters, 75 abstracts, and 5 significant publications where he is author and co-author.

    Expertise:
    Nuclear Medicine

    Specialty:
    Oncology, pediatric oncology, cardiovascular

    Professional Interests:
    Functional and multimodality imaging, development of oncology related radioligands, solid pediatric tumors, angiogenesis, myocardial and neoplastic response to hypoxia

    Education and Training:
    • Medical School: Universidad Complutense School of Medicine, Madrid, Spain
    • Internship: Imperial College, London - Cardiovascular Nuclear Medicine
    • Residency: San Carlos Hospital, Madrid, Spain - Nuclear Medicine
    • Residency: University of Pennsylvania School of Medicine - Nuclear Medicine
    • Fellowship: UCLA David Geffen School of Medicine Department of Medical and Molecular Pharmacology - Cardiovascular Nuclear Medicine
    • Fellowship: University of California, San Francisco Group for Leadership Collaborative Fellow
    • Clinical Research Fellow: Imperial College, London - Cardiovascular Nuclear Medicine
    • Doctor of Philosophy: Universidad Complutense School of Medicine, Madrid, Spain - Radiological Sciences
    • Colegio Oficial de Medicos, Madrid, Spain
    • Titulo de Especialista en Medicina Nuclear, Spain- Specialist Qualification in Nuclear Medicine
    • Specialist Register in the United Kingdom in Nuclear Medicine
    • General Medical Council, U.K.
    • Michigan Board of Medicine
    • Pennsylvania Controlled Substance Registration Certificate
    • Pennsylvania State Board of Medicine
    • California Medical Board
    • California Controlled Substance Registration Certificate (active)
    • American Board of Nuclear Medicine Board Certification
    • Certification Board in Nuclear Cardiology
    • Advanced Cardiac Life Support Certification (renewed)


    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Hernandez Pampaloni M, Facchetti L, Nardo L. Pitfalls in [¹8F]FDG PET imaging in gynecological malignancies. Q J Nucl Med Mol Imaging. 2016 Jun; 60(2):124-38. PMID: 26937887.
      View in: PubMed
    2. Pampaloni MH, Nazer B, Botvinick E. Erratum to: Isolated right ventricular cardiac sarcoidosis demonstrated by (18)FDG positron emission tomography. J Nucl Cardiol. 2015 Feb; 22(1):221. PMID: 25342216.
      View in: PubMed
    3. Pampaloni MH, Nardo L. PET/MRI radiotracer beyond ¹8F-FDG. PET Clin. 2014 Jul; 9(3):345-9. PMID: 25030398.
      View in: PubMed
    4. Hernandez Pampaloni M, Nazar B, Botvinick E. Isolated right ventricular cardiac sarcoidosis demonstrated by ¹8FDG positron emission tomography. J Nucl Cardiol. 2014 Jun; 21(3):652-4. PMID: 24429936.
      View in: PubMed
    5. Ibrahim SF, Ahronowitz I, McCalmont TH, Hernandez Pampaloni M, Ryan JL, Yu SS. 18F-fluorodeoxyglucose positron emission tomography-computed tomography imaging in the management of Merkel cell carcinoma: a single-institution retrospective study. Dermatol Surg. 2013 Sep; 39(9):1323-33. PMID: 23777452.
      View in: PubMed
    Miguel's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP